Feb 27, 2026Agilent’s GLP-1 CDMO business grows | Novartis plans 5th US radioligand manufacturing plant

Feb 26, 2026Charles River sells CDMO business | Big Pharma’s US investment plans short on details

Feb 25, 2026IDT Biologika looks to double sales by 2028 | AbbVie to build API plants in Chicago

Feb 24, 2026SCOTUS strikes down Trump tariffs, what’s next for pharma? | Siegfried’s 2026 outlook

Feb 21, 2026US biomanufacturing requires jumpstart in race with China | Lonza boosts advanced synthesis offering

Feb 20, 2026Piramal positions for supply chain uncertainty | Recipharm makes pilot, development investment

Feb 19, 2026Charles River’s CDMO business continues to struggle | J&J’s $1B cell therapy plant

Feb 18, 2026AI enters new phase in drug discovery | Recipharm sells Israel facility to Scinai

Feb 17, 2026Is WuXi AppTec a Chinese military company? | CARsgen expands CAR T manufacturing in China

Feb 14, 2026Lifecore sees tailwind from US onshoring | WuXi Vaccines gets ANVISA GMP approval for China site

Feb 13, 2026UK sets sights on biomanufacturing | Thermo Fisher links real-world data to clinical research

Feb 12, 2026Fujifilm’s UK biomanufacturing expansion | Moderna’s mRNA vaccine pact with Mexico

Feb 11, 20262025 was disappointing year for Recipharm | End-to-end US epinephrine injection manufacturing

Feb 10, 2026Regionalized vaccine manufacturing remains challenge | Bracco targets cell therapy manufacturing

Feb 7, 2026Cell and gene therapy needs innovative manufacturing | Samsung Biologics supports pandemic vaccines

Feb 6, 2026FDA drug approvals benefit CDMO sector | BMS inks multi-year deal for lentiviral vectors

Feb 5, 2026Charles River to close cell therapy CDMO site | Piramal expands tablet-in-capsule capabilities

Feb 4, 2026Eurofins embraces ownership over leasing | Automated manufacturing for gene-edited HSCs

Feb 3, 2026FDA launches PreCheck pilot program | Emerson tool automates batch record creation

Jan 31, 2026Lilly to build $3.5B Pennsylvania plant | US biomanufacturing investment report

Jan 30, 2026AstraZeneca pledges $15B China investment | Lonza’s Vacaville site to reach full potential next decade

Jan 29, 2026Catalent to close cell therapy hub | AstraZeneca evaluates robotics for cell therapy manufacturing

Jan 28, 2026Siegfried boosts US drug substance footprint | WuXi Biologics inks deal with HanchorBio

Jan 27, 2026UK sitting pretty with 0% US pharma tariff | Recipharm expands to meet FDA requirements

Jan 24, 2026Plant utilization fuels Samsung Biologics growth | Vaccine effort to improve manufacturing

Latest Edition